An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog Alfa (JOIN-us)
An 18-month Low-interventional Prospective, Multicentre Study to Assess Joint Outcomes in Patients With Haemophilia A or B on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog Alfa
Sponsor: IQVIA Pvt. Ltd
Terminated
The Sponsor has decided to stop the phase 4 study Sobi.HAEM89-007 (JOIN-us) due to a realignment of its development activities.~The clinical trial hasn't been terminated due to a change in the benefit-risk balance.
Other terminated trials from IQVIA Pvt. Ltd
More terminations from IQVIA Pvt. Ltd
Listed as NCT05856266, this PHASE4 trial focuses on Hemophilia A and Hemophilia B and remains terminated or withdrawn. Sponsored by IQVIA Pvt. Ltd, it has been updated 8 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE4
-
Feb 2025 — Sep 2025 [monthly]
Terminated PHASE4
-
Sep 2024 — Feb 2025 [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jan 2024 — Jul 2024 [monthly]
Terminated PHASE4
Status: Recruiting → Terminated
▶ Show 3 earlier versions
-
Oct 2023 — Jan 2024 [monthly]
Recruiting PHASE4
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Jun 2023 — Sep 2023 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- IQVIA Pvt. Ltd
- Swedish Orphan Biovitrum
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Alicante, Spain , Baia Mare, Romania , Barcelona, Spain , Belfast, United Kingdom , Bologna, Italy , Bordeaux, France , Brescia, Italy , Brno, Czechia , Bucharest, Romania and 41 more locations